Natixis Advisors L.P. Buys New Shares in Certara, Inc. (NASDAQ:CERT)

Natixis Advisors L.P. purchased a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,302 shares of the company’s stock, valued at approximately $586,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of CERT. Raymond James & Associates increased its position in Certara by 83.4% during the first quarter. Raymond James & Associates now owns 37,080 shares of the company’s stock worth $796,000 after buying an additional 16,861 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Certara by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 384,913 shares of the company’s stock worth $8,268,000 after acquiring an additional 4,107 shares during the last quarter. HighTower Advisors LLC raised its stake in Certara by 71.6% in the 1st quarter. HighTower Advisors LLC now owns 19,847 shares of the company’s stock valued at $440,000 after acquiring an additional 8,282 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Certara by 18.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock valued at $126,000 after purchasing an additional 905 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in Certara during the first quarter worth $111,000. Institutional investors own 67.26% of the company’s stock.

Certara Price Performance

CERT stock opened at $15.17 on Thursday. The company’s 50-day moving average price is $17.73 and its two-hundred day moving average price is $20.01. Certara, Inc. has a 12 month low of $10.60 and a 12 month high of $24.96. The company has a quick ratio of 3.43, a current ratio of 3.43 and a debt-to-equity ratio of 0.26. The firm has a market cap of $2.42 billion, a P/E ratio of 126.43, a P/E/G ratio of 1.14 and a beta of 1.46.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, August 9th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.02. Certara had a return on equity of 5.56% and a net margin of 5.45%. The firm had revenue of $90.45 million during the quarter, compared to analysts’ expectations of $92.04 million. On average, analysts anticipate that Certara, Inc. will post 0.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CERT shares. Barclays cut their target price on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, August 11th. Bank of America dropped their price target on Certara from $27.00 to $24.00 and set a “buy” rating for the company in a report on Tuesday, August 15th. Credit Suisse Group decreased their price objective on Certara from $27.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, August 10th. William Blair downgraded Certara from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Finally, TheStreet downgraded shares of Certara from a “c-” rating to a “d+” rating in a research note on Friday, June 16th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $21.13.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.